Autolus Therapeutics plc (AUTL) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.38
↓-27% vs avg
5yr avg: 3.24
30Y Low0.6·High10.0
ROE
↓
-95.2%
↑-25% vs avg
5yr avg: -76.3%
30Y Low-102%·High-18%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AUTL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Autolus Therapeutics plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $423M | $530M | $600M | $1.1B | $180M | $374M | $461M | $568M | $968M | — | — |
| Enterprise Value | $671M | $777M | $425M | $934M | $-177692540 | $132M | $361M | $383M | $779M | — | — |
| P/E Ratio → | -1.47 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 5.60 | 7.01 | 59.25 | 659.71 | 29.14 | 248.25 | 268.76 | 195.48 | 925.87 | — | — |
| P/B Ratio | 2.38 | 2.97 | 1.40 | 10.05 | 0.60 | 1.19 | 2.19 | 2.23 | 4.72 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AUTL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.28 | 41.98 | 549.82 | -28.69 | 87.45 | 210.50 | 131.79 | 745.00 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
AUTL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Autolus Therapeutics plc earns an operating margin of -372.4%. Operating margins have expanded from -10583.1% to -372.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -95.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -27.8% | -27.8% | -1293.5% | 100.0% | 100.0% | 100.0% | -7765.2% | -3525.1% | -4520.4% | 40.4% | 60.6% |
| Operating Margin | -372.4% | -372.4% | -2385.6% | -10583.1% | -2307.0% | -9314.8% | -17675.4% | -8513.8% | -5503.7% | -1383.2% | -1186.1% |
| Net Profit Margin | -381.4% | -381.4% | -2180.5% | -12272.3% | -2403.0% | -9429.1% | -8285.4% | -4258.9% | -2976.5% | -1165.2% | -1035.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -95.2% | -95.2% | -81.9% | -101.6% | -48.6% | -54.3% | -61.1% | -53.8% | -17.9% | -22.8% | -48.8% |
| ROA | -42.0% | -42.0% | -38.1% | -48.1% | -33.2% | -40.6% | -47.5% | -47.5% | -17.0% | -21.6% | -44.2% |
| ROIC | -62.3% | -62.3% | -204.1% | — | -1865.4% | -116.3% | -253.0% | -433.4% | -394.8% | -407.9% | -161.7% |
| ROCE | -45.5% | -45.5% | -45.9% | -46.4% | -34.8% | -44.0% | -112.4% | -102.4% | -33.0% | -26.8% | -55.1% |
AUTL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $247M ($352M total debt minus $104M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.97 | 1.97 | 0.12 | 0.48 | 0.08 | 0.22 | 0.26 | 0.10 | 0.00 | 0.00 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 1.39 | -0.41 | -1.67 | -1.20 | -0.77 | -0.48 | -0.73 | -0.92 | -0.96 | -0.91 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -7.66 | -7.66 | -25.91 | -3.62 | -15.68 | -127.54 | — | — | -4107.60 | — | — |
AUTL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Autolus Therapeutics plc's current ratio of 5.94x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 5.48x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 6.15x to 5.94x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.94 | 5.94 | 10.88 | 6.15 | 9.18 | 12.15 | 5.77 | 9.98 | 15.91 | 28.31 | 11.31 |
| Quick Ratio | 5.48 | 5.48 | 10.81 | 6.15 | 9.18 | 12.15 | 5.77 | 9.98 | 15.73 | 28.31 | 11.31 |
| Cash Ratio | 4.09 | 4.09 | 9.68 | 5.35 | 8.25 | 10.87 | 4.58 | 8.46 | 15.12 | 27.23 | 10.26 |
| Asset Turnover | — | 0.13 | 0.01 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.04 |
| Inventory Turnover | 2.91 | 2.91 | 34.08 | — | — | — | — | — | 21.87 | — | — |
| Days Sales Outstanding | — | 363.53 | 1739.88 | 225.06 | 1707.50 | 16.47 | 6317.80 | 3831.24 | 3234.69 | 1019.97 | 656.22 |
AUTL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Autolus Therapeutics plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | — | — |
| Shares Outstanding | — | $266M | $255M | $174M | $95M | $72M | $52M | $43M | $32M | $14M | $14M |
Peer Comparison
Compare AUTL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AUTLYou | $423M | -1.5 | — | — | -27.8% | -372.4% | -95.2% | -62.3% | — |
 KYMR | $8B | -27.1 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 FATE | $240M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 CRSP | $5B | -8.3 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $3B | -41.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 ALLO | $500M | -2.4 | — | — | — | — | -53.4% | -41.2% | — |
 CABA | $494M | -1.8 | — | — | — | — | -127.0% | -429.6% | — |
 LEGN | $5B | -18.4 | — | — | 60.3% | -13.3% | -29.1% | -12.7% | — |
 IONS | $13B | -32.2 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 RCKT | $360M | -1.6 | — | — | — | — | -60.3% | -62.4% | — |
 SANA | $913M | -3.4 | — | — | — | — | -118.7% | -74.4% | — |
| Healthcare Median | — | 22.5 | 14.3 | 19.1 | 63.6% | -4.8% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
AUTL — Frequently Asked Questions
Quick answers to the most common questions about buying AUTL stock.
What is Autolus Therapeutics plc's P/E ratio?
Autolus Therapeutics plc's current P/E ratio is -1.5x. This places it at the 50th percentile of its historical range.
What is Autolus Therapeutics plc's ROE?
Autolus Therapeutics plc's return on equity (ROE) is -95.2%. The historical average is -56.6%.
Is AUTL stock overvalued?
Based on historical data, Autolus Therapeutics plc is trading at a P/E of -1.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Autolus Therapeutics plc's profit margins?
Autolus Therapeutics plc has -27.8% gross margin and -372.4% operating margin.